Nanobac Pharmaceuticals, Incorporated
NNBP · OTC
12/31/2007 | 9/30/2007 | 6/30/2007 | 3/31/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.56 | 0.07 | -0.01 |
| FCF Yield | 0.00% | -0.62% | -1.65% | -2.00% |
| EV / EBITDA | -4.00 | -85.73 | 26.35 | -7.85 |
| Quality | ||||
| ROIC | 24.86% | 11.66% | 12.60% | 44.08% |
| Gross Margin | 15.52% | 19.66% | 21.79% | 15.00% |
| Cash Conversion Ratio | 0.09 | 0.24 | 0.40 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.06% | -70.12% | -61.10% | -47.58% |
| Free Cash Flow Growth | 44.92% | 29.74% | 10.00% | 52.81% |
| Safety | ||||
| Net Debt / EBITDA | -4.00 | -9.30 | 4.56 | -1.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.47 | 0.03 | 0.06 |
| Cash Conversion Cycle | -26,011.88 | -18,446.20 | -40,714.32 | -12,263.27 |